ReviewBiosensors2026
Progress in Optical Methods for the Detection of Two Core Blood Biomarkers of Alzheimer's Disease: Amyloid-Beta and Tau Proteins.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder worldwide. Early diagnosis of AD is crucial for delaying disease progression and improving patients' quality of life. Blood biomarkers, particularly amyloid-beta (Aβ) and Tau proteins along with their phosphorylated isoforms, show advantages such as convenient sampling, minimal invasiveness, and excellent repeatability. However, the extremely low concentrations of AD biomarkers in blood impose stringent requirements on the sensitivity, specificity, and anti-interference capability of detection methods. Optical methods provide promising analytical platforms to address these challenges in view of their intrinsic merits of high sensitivity and selectivity; rapid response; and potential for miniaturization. This review systematically summarizes the latest advances in optical methods for the detection of the two core AD blood biomarkers (Aβ and Tau), covering techniques such as colorimetry, fluorescence, chemiluminescence, surface plasmon resonance (SPR), and surface-enhanced Raman scattering (SERS). The sensing principles, design strategies, and analytical performances of these methods are discussed, with special emphasis on different signal amplification strategies. In addition, several challenges and future prospects are provided with a primary focus on single-molecule detection, insufficient sensitivity and stability, lack of validation with large clinical cohorts, and absence of standardization. This review aims to provide researchers with guidance for the rational development of high-performance optical methods to achieve early diagnosis of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.